FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143176313> ?p ?o ?g. }

• W2143176313 endingPage "578" @default.
• W2143176313 startingPage "572" @default.
• W2143176313 abstract "In the current paradigm of anticancer drug development, candidate compounds are evaluated by testing their in vitro potency against molecular targets relevant to carcinogenesis, their effect on cultured cancer cells, and their ability to inhibit cancer growth in animal models. We discuss the key assumptions inherent in these approaches. In recent years, great emphasis has been placed on selecting for development compounds with nanomolar in vitro potency, expecting that they will be efficacious and safer based on the assumption that they can be used at lower doses (the nanomolar rule). However, this rule ignores critical parameters affecting efficacy and toxicity such as physiochemical and absorption, distribution, metabolism and excretion properties, off-target effects, and multitargeting activities. Thus, uncritical application of the nanomolar rule may reject efficacious compounds or select ineffective or toxic compounds. We present examples of efficacious chemotherapeutic (alkylating agents, hormonal agents, antimetabolites, thalidomide, and valproic acid) and chemopreventive (aspirin and sulindac) agents having millimolar potency and compounds with nanomolar potency (cyclooxygenase-2 inhibitors) that, nevertheless, failed or proved to be unsafe. The effect of candidate drugs on animal models of cancer is a better predictor of human drug efficacy; particularly useful are tumor xenografts. Given the cost of failure at clinical stages, it is imperative to keep in mind the limitations of the nanomolar rule and use relevant in vivo models early in drug discovery to prioritize candidates. Although in vivo models will continue having a major role in cancer drug development, more robust approaches that combine high predictive ability with simplicity and low cost should be developed." @default.
• W2143176313 created "2016-06-24" @default.
• W2143176313 creator A5053483245 @default.
• W2143176313 creator A5069893086 @default.
• W2143176313 creator A5074378902 @default.
• W2143176313 date "2012-03-23" @default.
• W2143176313 modified "2023-09-23" @default.
• W2143176313 title "Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents: TABLE 1" @default.
• W2143176313 cites W1258890488 @default.
• W2143176313 cites W1565276921 @default.
• W2143176313 cites W1891860149 @default.
• W2143176313 cites W1975076018 @default.
• W2143176313 cites W1977071537 @default.
• W2143176313 cites W1984250533 @default.
• W2143176313 cites W1989049899 @default.
• W2143176313 cites W1991307214 @default.
• W2143176313 cites W1992252639 @default.
• W2143176313 cites W1993058852 @default.
• W2143176313 cites W2001415793 @default.
• W2143176313 cites W2001679453 @default.
• W2143176313 cites W2028435743 @default.
• W2143176313 cites W2030765289 @default.
• W2143176313 cites W2033028462 @default.
• W2143176313 cites W2038410983 @default.
• W2143176313 cites W2038448543 @default.
• W2143176313 cites W2052002840 @default.
• W2143176313 cites W2053127979 @default.
• W2143176313 cites W2062800226 @default.
• W2143176313 cites W2063709509 @default.
• W2143176313 cites W2064310618 @default.
• W2143176313 cites W2066936999 @default.
• W2143176313 cites W2078752778 @default.
• W2143176313 cites W2082823320 @default.
• W2143176313 cites W2087312216 @default.
• W2143176313 cites W2097235831 @default.
• W2143176313 cites W2097903769 @default.
• W2143176313 cites W2098426299 @default.
• W2143176313 cites W2104387817 @default.
• W2143176313 cites W2109185353 @default.
• W2143176313 cites W2111199038 @default.
• W2143176313 cites W2112046350 @default.
• W2143176313 cites W2117691193 @default.
• W2143176313 cites W2118767258 @default.
• W2143176313 cites W2120339010 @default.
• W2143176313 cites W2121348098 @default.
• W2143176313 cites W2121656289 @default.
• W2143176313 cites W2127773617 @default.
• W2143176313 cites W2131228625 @default.
• W2143176313 cites W2133986577 @default.
• W2143176313 cites W2136103407 @default.
• W2143176313 cites W2140103101 @default.
• W2143176313 cites W2147339810 @default.
• W2143176313 cites W2148168351 @default.
• W2143176313 cites W2157509061 @default.
• W2143176313 cites W2158131645 @default.
• W2143176313 cites W2171185186 @default.
• W2143176313 cites W2171194005 @default.
• W2143176313 cites W2327420869 @default.
• W2143176313 cites W2336169581 @default.
• W2143176313 cites W2342328556 @default.
• W2143176313 cites W4211136726 @default.
• W2143176313 cites W4377077308 @default.
• W2143176313 cites W54649336 @default.
• W2143176313 doi "https://doi.org/10.1124/jpet.112.191957" @default.
• W2143176313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3362883" @default.
• W2143176313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22448039" @default.
• W2143176313 hasPublicationYear "2012" @default.
• W2143176313 type Work @default.
• W2143176313 sameAs 2143176313 @default.
• W2143176313 citedByCount "39" @default.
• W2143176313 countsByYear W21431763132012 @default.
• W2143176313 countsByYear W21431763132013 @default.
• W2143176313 countsByYear W21431763132014 @default.
• W2143176313 countsByYear W21431763132015 @default.
• W2143176313 countsByYear W21431763132016 @default.
• W2143176313 countsByYear W21431763132017 @default.
• W2143176313 countsByYear W21431763132018 @default.
• W2143176313 countsByYear W21431763132019 @default.
• W2143176313 countsByYear W21431763132020 @default.
• W2143176313 countsByYear W21431763132021 @default.
• W2143176313 countsByYear W21431763132022 @default.
• W2143176313 countsByYear W21431763132023 @default.
• W2143176313 crossrefType "journal-article" @default.
• W2143176313 hasAuthorship W2143176313A5053483245 @default.
• W2143176313 hasAuthorship W2143176313A5069893086 @default.
• W2143176313 hasAuthorship W2143176313A5074378902 @default.
• W2143176313 hasBestOaLocation W21431763132 @default.
• W2143176313 hasConcept C150903083 @default.
• W2143176313 hasConcept C202751555 @default.
• W2143176313 hasConcept C207001950 @default.
• W2143176313 hasConcept C2776241388 @default.
• W2143176313 hasConcept C2778484676 @default.
• W2143176313 hasConcept C2780035454 @default.
• W2143176313 hasConcept C55493867 @default.
• W2143176313 hasConcept C57992300 @default.
• W2143176313 hasConcept C60644358 @default.
• W2143176313 hasConcept C64903051 @default.
• W2143176313 hasConcept C71924100 @default.

• next